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ABSTRACT 
Currently, one of the most important tasks is to improve the quality of 
medical services, which becomes possible in retrospective register 
analysis of medical and organizational technologies, which include 
algorithms for providing medical care, continuity of medical 
institutions, protocols for diagnosis and treatment of diseases. The 
stroke register was created on the basis of medical documentation of 
hospitals, which are the most typical for the Podillia region of Ukraine. 
Statistical processing of the results was performed using the licensed 
statistical package "Statistica 5.5" using parametric evaluation 
methods. Significant differences in the organization of the medical-
diagnostic process and approaches to treatment have been established 
between the two medical institutions of Vinnytsia in the dynamics of 
time. There was a positive trend in the time of stroke treatment, the use 
of drugs with a high degree of evidence and the coverage of patients 
with specialized, multidisciplinary care in a stroke. 
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Introduction. At present, there is no suitable alternative for the treatment of patients with acute 
cerebrovascular accident (ACA) in specialized stroke departments and centers. The experience of 
different countries shows that adequate, timely care for patients at the inpatient stage can be provided 
only in specialized centers, departments or units (stroke unit) [1]. The center includes a broader concept 
compared to the department: in the center, the treatment and diagnostic process begins immediately upon 
admission to the hospital, and therefore – with the assessment of the possibility of thrombolysis [2]. 
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In Ukraine, there is a question of establishing stroke centers and departments in both large cities 
and regional centers to provide highly qualified, specialized care to patients with ACA with the 
involvement of multidisciplinary teams consisting of specially trained medical staff [3]. Early discharge 
with subsequent accompaniment (supervision) of the patient in the context of multidisciplinary team care 
shows good results in patients, significantly reduces the time spent in the stroke unit and in the hospital 
in general [4, 5]. The establishment of these units in our country is the most effective strategy for 
providing care to patients with ACA. They are effective and cost-effective for the future, as they are 
more effective in reducing mortality and disability [6]. 
Treatment of the acute period of stroke includes basic therapy and prevention of somatic 
complications. Given the high mortality rate during the first month and the next 12 months after 
stroke, it is necessary to begin prevention of recurrent stroke in parallel with the provision of 
emergency specialized medical care to patients with ACA [7, 8]. The main principles of secondary 
prevention are the correction of risk factors and drug therapy. The strategy of individualized secondary 
stroke prevention is developed in the first day of the patient's stay in the hospital. It includes the use of 
statins, antihypertensive, antithrombotic drugs, correction of carbohydrate metabolism disorders, if 
necessary – surgical treatments [9, 10]. 
The purpose of the research – to study and compare the organization and level of medical 
care for stroke patients according to the registers of hospitals in Vinnytsia during 2017-2019. 
Material and methods of research. Data on stroke cases were obtained on the basis of 
medical documentation of medical institutions that are most typical for the Podillia region of Ukraine 
(Vinnytsia, most of Khmelnytsky, part of Ternopil, as well as small adjacent areas of Zhytomyr and 
Cherkasy regions). Data collection and processing was performed by a certified neurologist. 
We conducted a retrospective analysis of the results of medical histories of patients 
hospitalized for emergency appointments to the stroke unit of the Municipal Non-Profit Enterprise 
«Vinnytsia Regional Clinical Psychoneurological Hospital named after Academician 
O. I. Yushchenko of Vinnytsia Regional Council» (VRCPNH) or Vinnytsia City Clinical Hospital of 
Emergency Medical Services (VCCHEMS) for the period 2017-2019 with a diagnosis of ACA (Table 
1). After inpatient treatment, a RES-Q report form was completed on a case-by-case basis - a special 
report form in an international program developed by the European Stroke Society (ESO) ESO-EAST 
initiative. Since 2017, the hospitals we surveyed have been participating in this program. 
Table 1. Distribution of patients with ACA in VRCPNH or VCCHEMS stroke unit for 2017-2019. 
Groups 
surveyed 
Years of research 
Hospitals 
VRCPNH VCCHEMS 
men women men women 
General 
2017 307 209 351 335 
2018 312 187 310 306 
10 months of 2019 287 175 182 163 
Ischemic 
stroke 
2017 269 184 308 296 
2018 267 166 276 282 
10 months of 2019 248 152 162 153 
Hemorrhagic 
stroke 
2017 37 25 42 39 
2018 45 21 34 24 
10 months of 2019 39 23 20 10 
 
Data on the treatment were recorded: the use of certain groups of drugs (antihypertensive, 
antithrombolytic, statins), recanalization intervention, hematoma surgery. The quality indicators of the 
organization of the medical-diagnostic process were also considered: door-to-needle time, duration of 
treatment, hospitalization to the stroke unit. 
Statistical processing of the survey results was performed using the statistical package 
“Statistica 5.5” (licensed № AXXR910A374605FA) using parametric evaluation methods. 
Results and discussion. When comparing the percentage of patients who were hospitalized 
for stroke, VRCPNH found a significantly (p<0.05-0.001) higher value in patients with ischemic 
stroke (2017 – 76.9 % in men in general and 74.7 % with ischemic stroke; 70.3 % in women in general 
and 69.0 % with ischemic stroke; in 2018 – 97.8 % in men in general, 97.4 % with ischemic stroke and 
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100 % with hemorrhagic stroke; 98.9 % in women in general, 98.8 % with ischemic stroke and 100 % 
with hemorrhagic stroke; in 2019 – 97.2 % in men in general and 97.2 % with ischemic stroke; 98.3 % 
in women in general and 98.7% with ischemic stroke) compared to VCCHEMS (2017 – 57.0 % in 
men in general and 52.9 % with ischemic stroke; 58.5 % in women in general and 56.4 % with 
ischemic stroke; in 2018 – 74.5 % in men in general, 72.5 % with ischemic stroke and 91.5 % with 
hemorrhagic stroke; 76.5 % in women in general, 76.6 % with ischemic stroke and 75.0 % with 
hemorrhagic stroke; 2019 – 85.7 % of men in general and 85.2 % with ischemic stroke; 87.7 % in 
women in general and 86.9 % with ischemic stroke). 
In VRCPNH, the percentage of patients who were hospitalized in the stroke unit in the 
dynamics of 2017-2019 significantly (p<0.05-0.001) increased (2017 – 76.9 % in men in general, 
74.7 % with ischemic stroke and 91.9 % with hemorrhagic stroke; 70.3 % in women in general, 
69.0 % with ischemic stroke and 80.0 % with hemorrhagic stroke; in 2018 – 97.8 % in men in general, 
97.4 % with ischemic stroke and 100 % with hemorrhagic stroke; 98.9 % in women in general, 98.8 % 
with ischemic stroke and 100 % with hemorrhagic stroke; in 2019 – 97.2 % for men in general and 
97.2 % with ischemic stroke; 98.3 % for women in general and 98.7 % with ischemic stroke). 
VCCHEMS also significantly increased over time (p<0.01-0.001) the percentage of patients 
hospitalized for stroke (2017 – 57.0 % in men in general, 52.9 % in ischemic stroke; 58.5 % in women 
in general, 56.4 % in ischemic stroke; in 2018 – 74.5% in men in general, 72.5% with ischemic stroke; 
76.5 % in women in general, 76.6 % with ischemic stroke; in 2019 – 85.7 % in men in general and 
85.2 % with ischemic stroke; 87.7 % in women in general and 86.9 % with ischemic stroke). 
There were no significant differences in the intake of vitamin K antagonist by patients 
between medical institutions and in the dynamics of time. 
When comparing the percentage of patients receiving antiplatelet agents, VRCPNH in 2017-
2019 found a significantly (p<0.05-0.001) lower value (2017 – 68.7 % in men in general, 77.3 % with 
ischemic stroke; 66.5 % in women in general, 75.0 % with ischemic stroke; in 2018 – 69.9 % in men 
in general, 81.3 % with ischemic stroke; 66.8 % in women in general, 74.7 % with ischemic stroke; in 
2019 – 61.7 % in men in general and 71.4 % in ischemic stroke; 53.7 % in women in general and 
60.5 % in ischemic stroke) compared to VCCHEMS (2017 – 78.6 % in men in general, 85.7 % in 
ischemic stroke; 77.0 % in women in general, 84.5 % with ischemic stroke; 2018 – 83.5 % in men in 
general, 92.8 % with ischemic stroke; 83.7 % in women in general, 89.7 % with ischemic stroke; in 
2019 – 80.2 % in men in general and 88.9 % with ischemic stroke; 82.8 % in women in general and 
86.9 % in ischemic stroke). 
In VRCPNH, the percentage of patients receiving antiplatelet agents decreased significantly 
(p<0.05-0.01) over time (2017 – 68.7 % in men in general, 77.3 % in ischemic stroke; 66.5 % in women 
in general, 75.0 % with ischemic stroke; in 2018 – 69.9 % in men in general, 81.3 % with ischemic 
stroke; 66.8 % in women in general, 74.7 % with ischemic stroke; in 2019 – 61.7 % in men in general 
and 71.4 % with ischemic stroke; 53.7 % in women in general and 60.5 % with ischemic stroke). 
In VCCHEMS, the percentage of patients receiving antiplatelet agents increased significantly over 
time (p<0.05-0.01) (2017 – 78.6 % in men in general, 85.7 % with ischemic stroke; 77.0 % in women in 
general; in 2018 – 83.5 % in men in general, 92.8 % with ischemic stroke; 83.7% in women in general). 
When comparing the percentage of patients receiving dabigatran, VRCPNH in 2017-2019 found 
a significantly (p<0.05-0.001) higher value (2017 – 8.8 % in men in general, 10.0 % with ischemic 
stroke; 5.7 % in women in general, 6.5 % with ischemic stroke; in 2018 – 7.7 % in men in general, 9.0 % 
with ischemic stroke; 11.8 % in women in general, 13.3 % with ischemic stroke; in 2019 – 9.4 % in men 
in general and 10.9 % in ischemic stroke; 16.6 % in women in general and 19.1 % with ischemic stroke) 
compared to VCCHEMS (2017 – 0.9 % in men in general, 1.0 % with ischemic stroke’ 0.6 % in women 
in general, 0.7 % with ischemic stroke’ 2018 – 0.3 % in men in general, 0.4 % with ischemic stroke’ 
0.7 % in women in general, 0.7 % with ischemic stroke’ in 2019 – 2.7 % in men in general and 3.1 % 
with ischemic stroke’ 3.7 % in women in general and 3.9% in ischemic stroke). 
In VRCPNH, the percentage of patients receiving dabigatran increased significantly over time 
(p<0.05-0.01) (2017 – 8.8 % in men in general, 10.0 % in ischemic stroke; 5.7 % in women in general, 
6.5 % with ischemic stroke; in 2018 – 7.7 % in men in general, 9.0 % with ischemic stroke; 11.8 % in 
women in general, 13.3 % with ischemic stroke; in 2019 – 9.4 % in men in general and 10.9 % with 
ischemic stroke; 16.6 % in women in general and 19.1 % with ischemic stroke). 
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In VCCHEMS, the percentage of patients receiving dabigatran increased significantly 
(p<0.05-0.01) over time (2018 – 0.3 % in men in general, 0.4 % in ischemic stroke; 0.7 % in women in 
general and 0.7 % in ischemic stroke; 2019 – 2.7 % for men in general, 3.1 % with ischemic stroke; 
3.7 % for women in general and 3.9 % with ischemic stroke). 
When comparing the percentage of patients receiving rivaroxaban, VRCPNH in 2017 found a 
significantly (p<0.05) higher value (2017 – 5.3 % in women in general, 6.0 % with ischemic stroke) 
compared to VCCHEMS (2017 – 1.5 % in women in general, 1.7 % with ischemic stroke). 
In VCCHEMS, the percentage of patients receiving rivaroxaban significantly increased over 
time (p<0.05-0.01) (in 2017 – 1.5 % in women in general, 1.7 % with ischemic stroke; in 2018 – 1.0 % 
in men in general, 1.1 % with ischemic stroke; 5.6 % in women in general, 5.7 % with ischemic 
stroke; in 2019 – 3.8 % in men in general, 4.3 % with ischemic stroke; 5.5 % in women in general, 
5.9 % with ischemic stroke). 
When comparing the percentage of patients receiving other antithrombotic drugs, VRCPNH in 
2019 found a significantly higher value (p<0.01-0.001) (2019 – 4.5 % in men in general, 5.2 % with 
ischemic stroke; 6.3 % in women in general, 7.2 % with ischemic stroke) compared to VCCHEMS 
(2019 – 0% for men in general, 0 % with ischemic stroke; 0 % for women in general, 0 % with 
ischemic stroke). 
In VRCPNH, the percentage of patients receiving other antithrombotic drugs in 2019 
compared to 2017-2018 significantly (p<0.05-0.01) increased (2017 – 0.4 % in men with ischemic 
stroke; 1.4 % in women in general, 0 % with ischemic stroke; in 2018 – 0.6 % in men in general, 
0.4 % with ischemic stroke; 0 % in women in general, 0 % with ischemic stroke; in 2019 – 5.2 % in 
men with ischemic stroke; 6.3 % in women in general, 7.2 % with ischemic stroke). 
When comparing the percentage of patients who did not receive any antithrombotic drug, 
VRCPNH found a significantly (p<0.05) higher value (in 2017 – 67.6 % in men with hemorrhagic 
stroke; in 2019 – 11.4 % in women in general, 2.6 % with ischemic stroke) compared to VCCHEMS 
(2017 – 45.2 % in men with hemorrhagic stroke; in 2019 – 4.3 % in women in general, 0 % with 
ischemic stroke). 
In VRCPNH, the percentage of patients who did not receive any antithrombotic drug in 2018 
compared to 2017 and 2019 was significantly (p<0.05-0.01) higher (2017 – 67.6 % in men with 
hemorrhagic stroke; 60.0 % in women with hemorrhagic stroke; in 2018 – 90.5 % in women with 
hemorrhagic stroke; in 2019 – 94.9 % in men with hemorrhagic stroke; 69.6 % in women with 
hemorrhagic stroke). 
In VCCHEMS, the percentage of patients who did not receive any antithrombotic drug in 2017 
compared to 2018 and 2019 was significantly (p<0.05-0.01) higher in patients with ischemic stroke and 
significantly (p<0.05-0.01) less – in patients with hemorrhagic stroke (2017 – 45.2 % in men with 
hemorrhagic stroke; 9.9 % in women in general and 3.7 % in ischemic stroke; in 2018 – 91.2 % in men 
with hemorrhagic stroke; 6.2 % in women in general and 0.7 % in ischemic stroke; 2019 – 85.0 % in 
men with hemorrhagic stroke; 4.3 % in women in general and 0 % with ischemic stroke). 
When comparing the percentage of patients receiving statins, VRCPNH in 2017 found a 
significantly (p<0.01) higher, and in 2018 significantly (p<0.05) smaller its value in patients with 
ischemic stroke (2017 – 84.4 % in men in general and 92.9 % with ischemic stroke; in 2018 – 81.8 % 
in women in general and 91.1 % with ischemic stroke) compared to VCCHEMS (2017 – 75.5 % in 
men in general and 84.4 % with ischemic stroke; 2018 – 88.2 % in women in general and 95.7 % with 
ischemic stroke). 
In VRCPNH, during the study period, the percentage of men with hemorrhagic stroke who 
received statins decreased significantly (p<0.05-0.01) (2017 – 24.3 %; 2018 – 8.9 %; 2019 – 0 %). 
In VCCHEMS, the percentage of patients receiving statins in 2018 was significantly (p<0.05-
0.001) higher than in 2017 and 2019 (in 2017 - 75.5 % in men in general, 84.4 % with ischemic stroke; 
76.1 % in women in general, 84.1 % with ischemic stroke; in 2018 – 82.9 % in men in general, 92.8 % 
with ischemic stroke; 88.2 % in women in general, 95.7 % with ischemic stroke; in 2019 – 81.6 % in 
women in general and 86.3 % with ischemic stroke). During the study period, the percentage of 
women with hemorrhagic stroke who received statins decreased significantly (p<0.05-0.01) (in 2017 – 
15.4 %; in 2018 – 0 %). 
When comparing the percentage of patients who received antihypertensive drugs, VRCPNH in 
2017 found a significantly (p<0.05) higher, and in 2018-2019 significantly (p<0.05-0.001) its smaller 
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value (2017 – 76.0 % in men with hemorrhagic stroke; 89.5 % in women in general and 91.3 % with 
ischemic stroke; in 2018 – 83.7 % in men in general, 85.0 % with ischemic stroke and 92.9 % with 
hemorrhagic stroke; 81.8 % in women in general and 75.6 % in ischemic stroke; in 2019 – 88.7 % in 
men with ischemic stroke; 78.9 % in women in general and 79.6 % in ischemic stroke) compared to 
VCCHEMS (2017 – 64.3 % in men with hemorrhagic stroke; 82.1 % in women in general and 83.8 % 
with ischemic stroke; in 2018 – 93.2 % in men in general, 93.1 % with ischemic stroke and 94.1 % 
with hemorrhagic stroke; 94.1 % in women in general and 96.1 % with ischemic stroke; in 2019 – 
94.4 % in men with ischemic stroke; 92.6 % in women in general and 92.2 % with ischemic stroke). 
In VRCPNH, the percentage of men who received antihypertensive drugs increased significantly 
over time (p<0.05), and in women – on the contrary, significantly decreased (p<0.01) (in 2017 – 83.7 % 
for men in general; 89.5 % for women in general and 91.3 % with ischemic stroke; in 2018 – 83.7 % in 
men in general and 75.6 % with hemorrhagic stroke; in 2019 – 89.5 % in men in general and 94.9 % 
with hemorrhagic stroke; 78.9 % in women in general and 79.6 % with ischemic stroke). 
In VCCHEMS, the percentage of patients receiving antihypertensive drugs increased 
significantly over time (p<0.05-0.001) (2017 – 78.9 % in men in general, 81.2 % in ischemic stroke 
and 64.3 % in hemorrhagic stroke; 82.1 % in women in general, 83.8 % with ischemic stroke and 
69.2 % with hemorrhagic stroke; in 2018 – 93.2 % in men in general, 93.1 % with ischemic stroke and 
94.1 % with hemorrhagic stroke; 94.1 % in women in general, 96.1 % with ischemic stroke and 
70.8 % with hemorrhagic stroke; in 2019 – 93.4 % in men in general and 94.4 % with ischemic stroke; 
92.6 % in women in general, 92.2 % with ischemic stroke and 100% with hemorrhagic stroke). 
In VRCPNH, the average door-to-needle time in 2018 was significantly (p<0.05-0.001) lower 
compared to 2017 and 2019 (2017 – 27.32±1.31 in men in general and with ischemic stroke; 27.59±1.23 
in women in general and with ischemic stroke; 2018 – 21.66±1.05 in men in general and with ischemic 
stroke; 20.97±1.66 in women in general and with ischemic stroke; in 2019 – 24.70±1.02 in men in 
general and with ischemic stroke; 29.88±3.05 in women in general and with ischemic stroke). 
It is impossible to compare the average door-to-needle time between the two institutions and 
in the dynamics of VCCHEMS due to the lack of data in the medical histories of the latter (no 
recanalization procedure was performed). 
In VRCPNH, the average duration of treatment in 2017 was significantly (p<0.05-0.01) 
shorter, and in 2018 and 2019 – significantly (p<0.05-0.001) longer (2017 – 8.738±0.229 in men in 
total, 8.350±0.226 with ischemic stroke, 9.108±0.704 with hemorrhagic stroke; 8.350±0.226 in women 
in general and 8.232±0.241 with ischemic stroke; 2018 – 9.563±0.257 in men in general, 9.451±0.283 
with ischemic stroke; 9.012±0.314 in women in general and 9.033±0.342 with ischemic stroke; in 
2019 – 9.671±0.347 in women in general and 9.556±0.347 with ischemic stroke) compared with 
VCCHEMS (2017 – 9.521±0.162 in men in general, 9.304±0.162 with ischemic stroke, 11.05±0.59 
with hemorrhagic stroke; 9.371±0.225 in women in general and 9.235±0.231 with ischemic stroke; 
2018 – 8.493±0.179 in men in general, 8.150±0.169 with ischemic stroke; 8.446±0.159 in women in 
general and 8.355±0.153 with ischemic stroke; 2019 – 8.344±0.178 in women in general and 
8.313±0.185 with ischemic stroke). 
In VRCPNH, the average duration of treatment in 2017 was significantly (p<0.05-0.001) 
shorter than in 2018 and 2019 (2017 – 8.738±0.229 in men in general, 8.350±0.226 with ischemic 
stroke; 8.232±0.241 in women with ischemic stroke; 2018 – 9.563±0.257 in men in general, 
9.451±0.283 with ischemic stroke; 9.012±0.314 in women in general and 9.033±0.342 with ischemic 
stroke; in 2019 – 9.391±0.229 in men in general; 9.671±0.347 in women in general and 9.556±0.347 
with ischemic stroke). 
In VCCHEMS, the average duration of treatment also decreased significantly over time (p<0.05-
0.001) (2017 – 9.521±0.162 in men in general and 9.304±0.162 in ischemic stroke; 9.371±0.225 in 
women in general and 9.235±0.231 with ischemic stroke; 2018 – 8.493±0.179 in men in general, 
8.150±0.169 with ischemic stroke; 8.446 ± 0.159 in women in general and 8.355±0.153 with ischemic 
stroke; 2019 – 8.344±0.178 in women in general and 8.313±0.185 with ischemic stroke). 
There were no significant differences in the performance of surgical treatment of hematoma 
between medical institutions and in the dynamics of time. 
The implementation of the program to combat ischemic stroke, which introduced the method 
of thrombolytic reperfusion therapy, has allowed in recent years to achieve significant success in the 
treatment and rehabilitation of patients [11, 12, 13]. The method is based on the concept of ischemic 
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penumbra, which prevents or minimizes the development of irreversible damage to the substance of 
the brain [14, 15]. However, the time parameter ("door-to-needle time") can be a problematic aspect of 
the success and efficiency of this procedure. This indicator, along with the duration of treatment, the 
fact of hospitalization for stroke, in the analysis of the hospital register allows us to judge the 
organization of care for stroke patients and its impact on the consequences of the disease. 
Conclusions. Analysis of the dynamics of treatment duration for the period 2017-2019 shows 
its decrease in VCCHEMS and increase in VRCPNH. The rate of hospitalization in the stroke unit for 
both hospitals in 2019 compared to previous years has increased. A study of the duration of door-to-
needle time in VRCPNH shows its increase in 2019 compared to 2017 and 2018. There is an increase 
in the percentage of patients prescribed antithrombolytic drugs with a high degree of evidence and 
safety (rivaroxaban and dabigatran). The percentage of patients taking antihypertensive drugs and 
statins has increased, which may indicate both adherence to uniform treatment protocols and the fact 
that the percentage of patients with hypercholesterolemia and hypertension is increasing over time. 
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